Anemia is an issue of concern in the management of older patients with cancer. In this age group, the incidence and prevalence of both cancer and anemia increase with age.
Methods
The clinical consequences and the management of anemia, a common comorbid condition in older patients with cancer, are explored.
Results
Common causes of chronic anemia include iron deficiency and anemia of chronic disease. The prevalence of vitamin B12 deficiency due to reduced absorption of food-bound vitamin B12 also increases with aging. Although in many cases the cause of anemia is not found, a primary deficiency of erythropoietin may be at fault in at least some of these cases since the response of erythropoietin to anemia may decrease in individuals over age 70.
Conclusions
Anemia should not necessarily be ascribed to cancer or aging. The causes of anemia should be pursued and reversed, and hemoglobin levels should be maintained at a minimum of 12 g/dL in cancer patients undergoing chemotherapy who are responsive to erythropoietin. The reversal of anemia may offset or delay the accumulation of catabolic cytokines that may be responsible for functional decline in aging individuals.
References
1.
DayJ.C.Current Population Reports. Population Projections of the United States by Age, Sex, Race, and Hispanic Origin: 1995 to 2050. US Bureau of the Census. Washington, DC: US Government Printing Office; 1996: 5–1130. Available at: http://www.census.gov/prod/1/pop/p25-1130/p251130a.pdf. Accessed August 12, 2003.
2.
La VecchiaC., LucchiniF., NegriE.Cancer mortality in the elderly, 1960-1998: a worldwide approach. Oncol Spectr.2001; 2: 386–394.
3.
ExtermannM.Measurement and impact of comorbidity in older cancer patients. Crit Rev Oncol Hematol.2000; 35: 181–200.
4.
BalducciL., HardyC.L.Anemia of aging: a model of erythropoiesis in cancer patients. Cancer Control.1998; 5(suppl 1): 17–21.
5.
AníaB.J., SumanV.J., FairbanksV.F.Incidence of anemia in older people: an epidemiologic study in a well defined population. J Am Geriatr Soc.1997; 45: 825–831.
6.
PierelliL., PerilloA., GreggiS.Erythropoietin addition to granulocyte colony-stimulating factor abrogates life-threatening neutropenia and increases peripheral blood progenitor-cell mobilization after epirubicin, paclitaxel, and cisplatin combination chemotherapy: results of a randomized comparison. J Clin Oncol.1999; 17: 1288–1295.
7.
RatainM.J., SchilskyR.L., ChoiK.E.Adaptive control of etoposide administration: impact of interpatient pharmacodynamic variability. Clin Pharmacol Ther.1989; 45: 226–233.
8.
SilberJ.H., FridmanM., Di PaolaR.S.First-cycle blood counts and subsequent neutropenia, dose reduction or delay in early stage breast cancer therapy. J Clin Oncol.1998; 16: 2392–2400.
9.
ExtermannM., ChenH., CantorA.B.Predictors of toxicity from chemotherapy in older patients: a prospective pilot study. Proc Annu Meet Am Soc Clin Oncol.2000; 19: 2430. Abstract.
10.
SchrijversD., HighleyM., De BruynE.Role of red blood cells in pharmacokinetics of chemotherapeutic agents. Anticancer Drugs.1999; 10: 147–153.
GabriloveJ.Overview: erythropoiesis, anemia, and the impact of erythropoietin. Semin Hematol.2000; 37(suppl 6): 1–3.
13.
CleelandC.S., DemetriG.D., GlaspyJ.Identifying hemoglobin levels for optimal quality of life: results of an incremental analysis. Proc Annu Meet Am Soc Clin Oncol.1999; 18: 2215. Abstract.
14.
GabriloveJ.L., CleelandC.S., LivingstoneR.B.Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three-times-weekly dosing. J Clin Oncol.2001; 19: 2875–2882.
15.
LittlewoodT.J., BajettaE., NortierJ.W.Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol.2001; 19: 2865–2874.
CarsonJ.L., PosesR.M., SpenceR.K.Severity of anemia and operative mortality and morbidity. Lancet.1998; 1: 727–729.
18.
NelsonA.H., FleisherL.A., RosenbaumS.H.Relationship between postoperative anemia and cardiac morbidity in high-risk vascular patients in the intensive care unit. Crit Care Med.1993; 21: 860–866.
19.
ChavesP.H., VolpatoS., FriedL.Challenging the World Health Organization criteria for anemia in older women. J Am Geriatr Soc.2001; 49(suppl 3): 10.
20.
ChavesP.H., AsharB., GuralnikJ.M.Looking at the relationship between hemoglobin concentration and prevalent mobility difficulty in older women: should the criteria currently used to define anemia in older people be reevaluated?J Am Geriatr Soc.2002; 50: 1257–1264.
21.
GlaspyJ., BukowskiR., SteinbergD.Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice: Procrit Study Group. J Clin Oncol.1997; 15: 1218–1234.
22.
DemetriG.D., KrisM., WadeJ.Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. Procrit Study Group. J Clin Oncol.1998; 16: 3412–3425.
23.
SmithD.L.Anemia in the elderly. Am Fam Physician.2000; 62: 1565–1572.
24.
AníaB.J., SumanV.J., FairbanksV.F.Prevalence of anemia in medical practice: community versus referral patients. Mayo Clin Proc.1994; 69: 730–735.
25.
InelmenE.M., AlessioM.D., GattoM.R.A.Descriptive analysis of the prevalence of anemia in a randomly selected sample of elderly people at home: some results of an Italian multicentric study. Aging.1994; 6: 81–89.
26.
MansouriA., LipschitzD.A.Anemia in the elderly patient. Anemia.1992; 76: 619–630.
27.
QuaglinoD., GinaldiL., FuriaN.The effect of age on hemostasis. Aging (Milano).1996; 8: 1–12.
28.
TranK.H., UddenM.M., TaffetG.E.Erythropoietin regulation of hematopoiesis is preserved in healthy elderly people. Clin Res.1993; 41: 116a.
29.
ZauberN.P., ZauberA.G.Hematologic data of healthy very old people. JAMA.1987; 257: 2181–2184.
30.
DuthieE.Physiology of aging: relevance to symptom perceptions and treatment tolerance. In: BalducciL., LymanG.H., ErshlerW.B.Comprehensive Geriatric Oncology.Amsterdam: Harwood Academic Publishers; 1998.
31.
BalducciL., HardyC.L., LymanG.H.Hematopoietic growth factors in the older cancer patient. Curr Opin Hematol.2001; 8: 170–187.
32.
CohenH.J., PiperC.S., HarrisT.Markers of inflammation and coagulation predict decline in function and mortality in community dwelling elderly. J Am Geriatr Soc.2001; S1: A3.
33.
HamermanD., BermanJ.W., AlbersG.W.Emerging evidence for inflammation in conditions frequently affecting older adults: report of a symposium. J Am Geriatr Soc.1999; 47: 1016–1025.
34.
ErshlerW.B.Biological interactions of aging and anemia: a focus on cytokines. J Am Geriatr Soc.2003; 51(suppl): 8–21.
35.
PaquetteR.L.Diagnosis and management of aplastic anemia and myelodysplastic syndrome. Oncology (Huntington).2002; 16(suppl 10): 153–161.
36.
LudwigH.Anemia and hematological malignancies: what are the treatment options?Semin Oncol.2002; 29(suppl 8): 45–54.
37.
JoostenE., PelemansW., HieleM.Prevalence and causes of anaemia in a geriatric hospitalized population. Gerontology.1992; 38: 111–117.
38.
AndersonS., BrennerB.M.Effects of aging on the renal glomerulus. Am J Med.1986; 80: 435–442.
39.
LeveyA.S., BoschJ.P., LewisJ.B.A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of diet in renal disease study group. Ann Intern Med.1999; 130: 461–470.
40.
KrantzS.B.Pathogenesis and treatment of the anemia of chronic disease. Am J Med Sci.1994; 307: 353–359.
41.
ChiariM.M., BagnoliR., De LucaP.Influence of acute inflammation on iron and nutritional status indexes in older inpatients. J Am Geriatr Soc.1995; 43: 767–771.
42.
MurphyP.T., HutchinsonR.M.Identification and treatment of anaemia in older patients. Drugs Aging.1994; 4: 113–127.
43.
AbramsonS.D., AbramsonN.“Common” uncommon anemias. Am Fam Physician.1999; 59: 851–858.
DalyM.P.Anemia in the elderly. Am Fam Physician.1989; 39: 129–136.
46.
NafzigerJ., PaillaK., LucianiL.Decreased erythropoietin responsiveness to iron deficiency anemia in the elderly. Am J Hematol.1993; 43: 172–176.
47.
KarioK., MatsuoT., KodomaK.Reduced erythropoietin secretion in senile anemia. Am J Hematol.1992; 41: 252–257.
48.
CarpenterM.A., KendallR.G., O'BrienA.E.Reduced erythropoietin response to anaemia in elderly patients with normocytic anaemia. Eur J Haematol.1992; 49: 119–121.
49.
TongE.M., NissensonA.R.Erythropoietin and anemia. Semin Nephrol.2001; 21: 190–203.
50.
Chronic Kidney Disease. In: Healthy People 2010. Vol 1. Objectives for Improving Health. Part A: Focus Areas 1-14.US Dept of Health and Human Services; 2000.
51.
BesarabA., FlahartyK.K., ErslevA.J.Clinical pharmacology and economics of recombinant human erythropoietin in end-stage renal disease: the case for subcutaneous administration. J Am Soc Nephrol.1992; 2: 1405–1416.
52.
CarmelR.Prevalence of undiagnosed pernicious anemia in the elderly. Arch Intern Med.1996; 156: 1097–1100.
53.
SumnerA.E., ChinM.M., AbrahmJ.L.Elevated methylmalonic acid and total homocysteine levels show high prevalence of vitamin B12 deficiency after gastric surgery. Ann Intern Med.1996; 124: 469–476.
54.
NormanE.J., MorrisonJ.A.Screening elderly populations for cobalamin (vitamin B12) deficiency using the urinary methylmalonic acid assay by gas chromatography mass spectrometry. Am J Med.1993; 94: 489–494.
55.
GoodnoughL.T., PriceT.H., ParvinC.A.The endogenous erythropoietin response and the erythropoietic response to blood loss anemia: the effects of age and gender. J Lab Clin Med.1995; 126: 57–64.
56.
PowersJ.S., KrantzS.B., CollinsJ.C.Erythropoietin response to anemia as a function of age. J Am Geriatr Soc.1991; 39: 30–32.
57.
FriedL.P., StorerD.J., KingD.E.Diagnosis of illness presentation in the elderly. J Am Geriatr Soc.1991; 39: 117–123.
58.
LucianiA., BalducciL.Age and multiple primary malignancies. Semin Oncol. In press.
59.
AhluwaliaN., Lammi-KeefeC.J., BendelR.B.Iron deficiency and anemia of chronic disease in elderly women: a discriminate-analysis approach for differentiation. Am J Clin Nutr.1995; 61: 590–596.
60.
IzaksG.J., WestendorpR.G., KnookD.L.The definition of anemia in older persons. JAMA.1999; 281: 1714–1717.
61.
KikuchiM., InagakiT., ShinagawaN.Five-year survival of older people with anemia: variation with hemoglobin concentration. J Am Geriatr Soc.2001; 49: 1226–1228.
62.
GagnonD.R., ZhangT.J., BrandF.N.Hematocrit and the risk of cardiovascular disease-the Framingham study: a 34-year follow-up. Am Heart J.1994; 127: 674–682.
63.
RiegerP.T.Assessment and epidemiologic issues related to fatigue. Cancer.2001; 96(suppl): 1733–1736.
64.
RespiniD., JacobsenP.B., ThorsC.The prevalence and correlates of fatigue in older cancer patients. Crit Rev Oncol Hematol.2003; 47: 273–279.
65.
LiaoS., FerrellB.A.Fatigue in an older population. J Am Geriatr Soc.2000; 48: 426–430.
66.
GutsteinH.B.The biologic basis of fatigue. Cancer.2001; 92(suppl): 1678–1683.
67.
MetivierF., MarchaisS.J., GuerinA.P.Pathophysiology of anaemia: focus on the heart and blood vessels. Nephrol Dial Transplant.2000; 15(suppl 3): 14–18.
68.
LevinA., SingerJ., ThompsonC.R.Prevalent left ventricular hypertrophy in the predialysis population: identifying opportunities for intervention. Am J Kidney Dis.1996; 27: 347–354.
69.
SilverbergD.S., WexlerD., BlumM.The use of subcutaneous erythropoietin and intravenous iron for the treatment of the anemia of severe, resistant congestive heart failure improves cardiac and renal function and functional cardiac class, and markedly reduces hospitalizations. J Am Coll Cardiol.2000; 35: 1737–1744.
70.
WuW.C., RathoreS.S., WangY.Blood transfusions in elderly patients with acute myocardial infarction. N Engl J Med.2001; 345: 1230–1236.
71.
BeardC.M., KokmenE., O'BrienP.C.Risk of Alzheimer's disease among elderly patients with anemia: population-based investigations in Olmsted County, Minnesota. Ann Epidemiol.1997; 7: 219–224.
72.
CellaD.The Functional Assessment of Cancer Therapy - Anemia (FACT-An) Scale: a new tool for the assessment of outcomes in cancer anemia and fatigue. Semin Hematol.1997; 34(suppl 2): 13–19.
73.
KatzI.R., Beaston-WimmerP., ParmeleeP.Failure to thrive in the elderly: exploration of the concept and delineation of psychiatric components. J Geriatr Psychiatry Neurol.1993; 6: 161–169.
74.
YellenS.B., CellaD.F., WebsterK.Measuring fatigue and other anemia-related symptoms with the Functional Assessment of Cancer Therapy (FACT) measurement system. J Pain Symptom Manage.1997; 13: 63–74.
75.
NissensonA.R.Epoetin and cognitive function. Am J Kidney Dis.1992; 20(suppl 1): 21–24.
76.
PickettJ.L., ThebergeD.C., BrownW.S.Normalizing hematocrit in dialysis patients improves brain function. Am J Kidney Dis.1999; 33: 1122–1130.
77.
MarcantonioE.R., FlackerJ.M., MichaelsM.Delirium is independently associated with poor functional recovery after hip fracture. J Am Geriatr Soc.2000; 48: 618–624.
78.
MeltonLJIII, KhoslaS., CrowsonC.S.Epidemiology of sarcopenia. J Am Geriatr Soc.2000; 48: 625–630.
79.
AslaniA., SmithR.C., AllenB.J.The predictive value of body proteins for chemotherapy induced toxicity. Cancer.2000; 88: 796–803.
